Oliver Bandmann
YOU?
Author Swipe
View article: Secondary nucleation of α-Synuclein drives Mitochondria dysfunctions and Lewy body formation in Parkinson’s Disease
Secondary nucleation of α-Synuclein drives Mitochondria dysfunctions and Lewy body formation in Parkinson’s Disease Open
The seeding of α-Synuclein (αSyn) is a key driver of Lewy pathology propagation in Parkinson’s disease (PD) and forms the basis for recent diagnostic success. However, it remains unclear how the structural and biochemical features of αSyn …
View article: Neuroprotection in Parkinson Disease
Neuroprotection in Parkinson Disease Open
Parkinson disease (PD) is a progressive neurodegenerative condition characterised by tremor, bradykinesia and rigidity, as well as other motor and non-motor symptoms, for which no effective disease-modifying treatments have been discovered…
View article: Loneliness, social isolation, and effects on cognitive decline in patients with dementia: A retrospective cohort study using natural language processing
Loneliness, social isolation, and effects on cognitive decline in patients with dementia: A retrospective cohort study using natural language processing Open
INTRODUCTION The study aimed to compare cognitive trajectories between patients with reports of social isolation and loneliness and those without. METHODS Reports of social isolation, loneliness, and Montreal Cognitive Assessment (MoCA) sc…
View article: Treatment Selection and Prioritization for the <scp>EJS ACT</scp>‐<scp>PD MAMS</scp> Trial Platform
Treatment Selection and Prioritization for the <span>EJS ACT</span>‐<span>PD MAMS</span> Trial Platform Open
Background There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment o…
View article: Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease
Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease Open
Objective The aim of our study is to better understand the genetic architecture and pathological mechanisms underlying neurodegeneration in idiopathic Parkinson's disease (iPD). We hypothesized that a fraction of iPD patients may harbor a …
View article: Multimodal assessment of mitochondrial function in Parkinson's disease
Multimodal assessment of mitochondrial function in Parkinson's disease Open
The heterogenous aetiology of Parkinson's disease is increasingly recognized; both mitochondrial and lysosomal dysfunction have been implicated. Powerful, clinically applicable tools are required to enable mechanistic stratification for fu…
View article: Clinical Trial Highlights: Modulators of Mitochondrial Function
Clinical Trial Highlights: Modulators of Mitochondrial Function Open
Mitochondria are involved in many dynamic processes, including their role in the production of the cell's energy currency, adenosine triphosphate (ATP).This production is carried out through a complex chain of chemical reactions, followed …
View article: A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (<scp>UDCA)</scp> in Parkinson's Disease
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (<span>UDCA)</span> in Parkinson's Disease Open
Background Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across a range of preclinical in v…
View article: Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency
Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency Open
Heterozygous variants in GBA1, encoding glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's disease (PD). Moreover, sporadic PD patients also have a substantial reduction of GCase activity. Genetic variants …
View article: 3α,7-Dihydroxy-14(13→12)abeo-5β,12α(H),13β(H)-cholan-24-oic Acids Display Neuroprotective Properties in Common Forms of Parkinson’s Disease
3α,7-Dihydroxy-14(13→12)abeo-5β,12α(H),13β(H)-cholan-24-oic Acids Display Neuroprotective Properties in Common Forms of Parkinson’s Disease Open
Parkinson’s Disease is the most common neurodegenerative movement disorder globally, with prevalence increasing. There is an urgent need for new therapeutics which are disease-modifying rather than symptomatic. Mitochondrial dysfunction is…
View article: Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease Open
Importance Current treatments manage symptoms of Parkinson disease (PD), but no known treatment slows disease progression. Preclinical and epidemiological studies support the potential use of statins as disease-modifying therapy. Objective…
View article: Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease
Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease Open
Background Cognitive impairment is common in neurological presentations of Wilson's disease (WD). Various domains can be affected, and subclinical deficits have been reported in patients with hepatic presentations. Associations with imagin…
View article: The master energy homeostasis regulator PGC-1α couples transcriptional co-activation and mRNA nuclear export
The master energy homeostasis regulator PGC-1α couples transcriptional co-activation and mRNA nuclear export Open
PGC-1α plays a central role in maintaining the mitochondrial and energy metabolism homeostasis, linking external stimuli to the transcriptional co-activation of genes involved in adaptive and age-related pathways. The carboxyl-terminus enc…
View article: Neuroimaging correlates of brain injury in Wilson’s disease: a multimodal, whole-brain MRI study
Neuroimaging correlates of brain injury in Wilson’s disease: a multimodal, whole-brain MRI study Open
Wilson’s disease is an autosomal-recessive disorder of copper metabolism with neurological and hepatic presentations. Chelation therapy is used to ‘de-copper’ patients but neurological outcomes remain unpredictable. A range of neuroimaging…
View article: Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis
Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis Open
Visual hallucinations (VH) are common in Parkinson's disease and dementia with Lewy bodies, two forms of Lewy body disease (LBD), but the neural substrates and mechanisms involved are still unclear. We conducted meta-analyses of voxel-base…
View article: Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease Open
Background Outcomes are unpredictable for neurological presentations of Wilson's disease (WD). Dosing regimens for chelation therapy vary and monitoring depends on copper indices, which do not reflect end‐organ damage. Objective To identif…
View article: Targeting mechanisms in cognitive training for neurodegenerative diseases
Targeting mechanisms in cognitive training for neurodegenerative diseases Open
"Cognitive training" (CT) is a label used to describe paper-and-pen or computerized exercises designed to engage a desired set of mental skills for the purpose of enhancing neurocognitive functioning. Although the literature on the topic i…
View article: Acid Sphingomyelinase Deficiency Normalizes Neuronal Function in GCase Deficiency - Unexpected Biological Rescue Effect of Combined Genetic Risk Factors for Parkinson’s Disease
Acid Sphingomyelinase Deficiency Normalizes Neuronal Function in GCase Deficiency - Unexpected Biological Rescue Effect of Combined Genetic Risk Factors for Parkinson’s Disease Open
Background The additive mechanistic effect of genetic risk variants for Parkinson’s disease (PD) is a plausible but largely unproven hypothesis. We investigated the mechanistic interaction between the two lysosomal PD risk genes glucocereb…
View article: Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study
Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study Open
Introduction There are no disease-modifying treatments for Parkinson’s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of t…
View article: Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease
Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease Open
This study provides Class III evidence that serum FGF-21, serum GDF-15, and blood mtDNA copy number levels do not distinguish patients with PD from healthy controls. There was no diagnostic uncertainty between patients with PD and healthy …
View article: C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis
C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis Open
Energy metabolism is altered in amyotrophic lateral sclerosis and its animal models. Using metabolic profiling, Allen et al. reveal a loss of metabolic flexibility in induced astrocytes derived from patients with C9orf72 ALS, caused by def…
View article: Unexpected opposing biological effect of genetic risk factors for Parkinson’s disease
Unexpected opposing biological effect of genetic risk factors for Parkinson’s disease Open
The additive effect of genetic risk variants on overall disease risk is a plausible but frequently unproven hypothesis. To test this hypothesis, we assessed the biological effect of combined glucocerebrosidase (GCase) and acid sphingomyeli…
View article: The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy
The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy Open
Background Studies on early‐onset presentations of progressive supranuclear palsy (PSP) have been limited to those where a rare monogenic cause has been identified. Here, we have defined early‐onset PSP (EOPSP) and investigated its genetic…
View article: Reduced habit-driven errors in Parkinson’s Disease
Reduced habit-driven errors in Parkinson’s Disease Open
Parkinson’s Disease can be understood as a disorder of motor habits. A prediction of this theory is that early stage Parkinson’s patients will display fewer errors caused by interference from previously over-learned behaviours. We test thi…